H1 beat; it's the mid-term outlook that is worth betting on
08/08/25 -"H1 results surpassed expectations, driven by a healthy performance from the Injectables segment. Also, the management reiterated its full-year guidance. Nonetheless, given the downward revision in ..."
Pages
53
Language
English
Published on
08/08/25
You may also be interested by these reports :
08/08/25
H1 results surpassed expectations, driven by a healthy performance from the Injectables segment. Also, the management reiterated its full-year ...
08/08/25
Genmab’s Q2 results exceeded market expectations, driven by strong performance across key offerings, resulting in significant profitability growth. ...
08/08/25
The Q2 results fell short of consensus, as growth in Life Science and Healthcare was materially offset by weakness in the Electronics business. ...
07/08/25
The Q2/H1 results exceeded expectations, putting the firm on track towards achieving its full-year targets. As expected, Biosimilars drove the show, ...